Rondo Therapeutics to Showcase Next-Generation CD28 Bispecific Platform at Upcoming Therapeutic Antibody Conferences finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including
Company shared progress from its proprietary A-Kine platform for engineering of target-selective, cis-acting cytokine immunotherapies at 2022 PEGS Europe Protein and Antibody Engineering Summit Data
Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) presents scientific updates in oral and poster presentations selected for international conferences: theSociety
New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI) and Bifunctional Therapy Targeting PD1 and IL-7 (BiCKI-IL-7) For Cancer Immunotherapy Regulatory News: OSE Immunotherapeutics